Search Within

Pallawi Torka

Formats
  1. Meeting Abstract (43)
  2. Journal Article (14)
  3. Research Letter (3)
  4. Correspondence (2)
  5. Editorial (1)
  6. Review (1)
Groups
  1. Center for Hematologic Malignancies (31)
  2. Department of Medicine (31)
  3. Hematologic Malignancies, Division of (31)
  4. Lymphoma (31)
  5. Hematology-Oncology Fellows (29)
  6. Sloan Kettering Institute Postdocs (28)

More Groups

People
  1. Paul Hamlin (30)
  2. Anita Kumar (28)
  3. Paola Ghione (28)
  4. Andrew Zelenetz (27)
  5. Gilles Salles (27)
  6. Lorenzo Falchi (27)

More People

Years
  1. 2025 (10)
  2. 2024 (27)
  3. 2023 (27)
Publications
  1. Blood (39)
  2. Blood Cancer Journal (4)
  3. Hematological Oncology (4)
  4. Blood Advances (3)
  5. Clinical Lymphoma, Myeloma and Leukemia (2)
  6. Journal of Clinical Oncology (2)

More Publications

Publishers
  1. American Society of Hematology (42)
  2. Elsevier Inc. (4)
  3. Nature Publishing Group (4)
  4. Wiley Blackwell (4)
  5. Biomed Central Ltd (3)
  6. American Society of Clinical Oncology (2)

More Publishers

Results (64)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Final results of a phase I/II trial of carfilzomib + R-CHOP for frontline treatment of patients with non-germinal center diffuse large B-cell lymphoma (DLBCL)
    Meeting Abstract

    Hill, B. T.; Torka, P.; Hernandez-Ilizaliturri, F. J.; Dean, R. M.; Jagadeesh, D.; Karamlou, K.; Fu, C. L.; Winter, A.; Krauspe, E.; Zhou, J.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Antigen-specific t-cell repertoire responses following COVID-19 vaccination are intact in majority of patients with B-cell lymphoid malignancies on active therapy
    Meeting Abstract

    Goel, S.; Griffiths, E. A.; Segal, B.; Nemeth, M.; Cortese, M. J.; Hernandez-Ilizaliturri, F. J.; Banbury, B.; Schumacher, E.; Torka, P.; Ghione, P.
    Blood (2023)

    Fulltext@MSK | Save
  • Responses and outcomes after second-line therapy in transplant-eligible patients with DLBCL relapse over 1 year after first-line therapy
    Meeting Abstract

    Qualls, D. A.; Shah, G. L.; Shouval, R.; Caron, P.; David, K. A.; Falchi, L.; Ghione, P.; Hamlin, P. A.; Horwitz, S. M.; Intlekofer, A. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Impact of early histological transformation on survival in patients with follicular lymphoma
    Meeting Abstract

    Luttwak, E.; Qiu, A.; Okwali, M.; Rivas-Delgado, A.; Isgor, I.; Boardman, A. P.; Caron, P.; David, K. A.; Falchi, L.; Ghione, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Infectious complications in patients with relapsed or refractory (R/R) Non-Hodgkin's lymphoma (NHL) treated with the anti-CD20xCD3 bispecific antibody (BsAb) mosunetuzumab
    Meeting Abstract

    Shahid, Z.; Okwali, M.; Joseph, A.; Seo, S. K.; Lue, J. K.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; Ghione, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of limited stage high grade B-cell lymphoma with MYC/BCL2 and/or BCL6 rearrangements: A single center experience
    Meeting Abstract

    Lue, J. K.; Luttwak, E.; Caron, P.; Boardman, A. P.; David, K. A.; Rivas-Delgado, A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; Hamlin, P. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Brentuximab vedotin-based regimens for older patients with newly diagnosed classical Hodgkin lymphoma -Real world experience
    Meeting Abstract

    Luttwak, E.; Ganesan, N.; Boardman, A. P.; Caron, P.; David, K. A.; Rivas-Delgado, A.; Falchi, L.; Ghione, P.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Potent CD8+T-cell proliferation and effector differentiation following subcutaneous (SC) mosunetuzumab administration in patients with untreated, high tumor-burden follicular lymphoma (FL)
    Meeting Abstract

    Falchi, L.; Lin, Y. H.; Melendez, L.; Ghione, P.; Owens, C.; Hamlin, P. A.; Lue, J. K.; Epstein-Peterson, Z. D.; Kumar, A.; Palomba, M. L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Treatment patterns and outcomes for patients with classic Hodgkin lymphoma (cHL) and cardiomyopathy with low ejection fraction (EF): Real-world evidence (RWE) from 16 US academic centers
    Meeting Abstract

    Annunzio, K.; McLaughlin, E.; Voorhees, T.; Shea, L. K.; Sumransub, N.; Rose, A.; Olszewski, A. J.; Bailey, N.; Patel, K.; Moyo, T. K.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Impact of large cells and Ki-67% on outcomes in patients with newly diagnosed marginal zone lymphoma - Results from a multicenter cohort study
    Meeting Abstract

    Epperla, N.; Grover, N. S.; Annunzio, K.; Watkins, M. P.; Torka, P.; Karmali, R.; Anampa-Guzmán, A. C.; Oh, T. S.; Reves, H.; Tavakkoli, M.; more...
    Blood (2023)

    Fulltext@MSK | Save